Evolysse FORM
Symatese · Decision date Dec 18, 2025
What did the FDA approve?
FDA records P240022/S003 as a supplement to PMA P240022, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 18, 2025.
FDA approval order statement
Approval for changes to the Informed Consent Form used in the Post-Approval Study.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Dec 18, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240022/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Symatese
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Dec 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240022/S001 · Related supplement
EVOLYSSE FORM and EVOLYSSE SMOOTH
P240022/S003 received
Application receipt date recorded by FDA.
P240022/S003 · FDA decision
Normal 180 Day Track No User Fee
P240022/S004 · Related supplement
Evolysse Injectable Hyaluronic Acid
P240022/S005 · Related supplement
Evolysse Smooth; Evolysse Form
Timeline entries are records held by MedtechLedger for P240022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EVOLYSSE FORM and EVOLYSSE SMOOTHP240022/S001 | Symatese | PMA supplement | Sep 3, 2025 | FDA |
Evolysse Injectable Hyaluronic AcidP240022/S004 | Symatese | PMA supplement | Dec 19, 2025 | FDA |
Evolysse Smooth; Evolysse FormP240022/S005 | Symatese | PMA supplement | Feb 27, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Symatese
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Zi Les Troques, Chaponost, 69630
Sources and methodology
- Original FDA record: P240022/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




